Following tumor establishment, NT, IL-7-CAR-T cells, and anti-PD-1 antibodies were administered intravenously to the tumor-bearing mice, with tumor progression monitored at various time points (Fig. 4C). The gene discussed is IL7; the disease is neoplasm.